This announcement contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical fact are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, some of which are beyond the Company's control that may cause the actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Zhaoke Ophthalmology Limited
兆科眼科有限公司

(Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands)

(Stock Code: 6622)

INTERIM RESULTS ANNOUNCEMENT
FOR THE SIX MONTHS ENDED JUNE 30, 2026

The Board and the Directors of our Company are pleased to announce the unaudited consolidated interim results of our Group for the six months ended June 30, 2026, together with the comparative figures for the corresponding period in 2025 as follows. The interim financial report has been reviewed by the Audit Committee.

In this announcement, "Zhaoke Ophthalmology", "we", "us" and "our" refer to the Company or where the context otherwise requires, the Group.

FINANCIAL HIGHLIGHTS

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue	**18,828**	15,803
Cost of sales	**(9,080)**	(7,336)
Gross profit	**9,748**	8,467
Other income	**14,740**	26,268
Other net gain	**21,681**	20,012
R&D expenses	**(105,751)**	(113,050)
General and administrative expenses	**(33,210)**	(30,559)
Selling and distribution expenses	**(24,825)**	(23,421)
Finance costs	**(4,976)**	(4,340)
Income tax	**–**	–
Loss for the period	**(122,593)**	(116,623)
Total comprehensive income for the period	**(191,112)**	(195,373)
Non-HKFRS Accounting Standards adjusted loss for the period[(1)]	**(116,105)**	(115,274)

Note:

(1) NON-HKFRS ACCOUNTING STANDARDS MEASURES

Non-HKFRS Accounting Standards adjusted loss for the period is defined as loss for the period adjusted by adding back equity-settled share-based payment expenses. The following table reconciles our non-HKFRS Accounting Standards adjusted loss for the period with our loss for the period.

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Loss for the period	**(122,593)**	(116,623)
Add:		
Equity-settled share-based payment expenses	**6,488**	1,349
Non-HKFRS Accounting Standards adjusted loss for the period	**(116,105)**	(115,274)

MANAGEMENT DISCUSSION AND ANALYSIS

OVERVIEW

Zhaoke Ophthalmology is a leading ophthalmic pharmaceutical company dedicated to the research, development, manufacture and commercialization of therapies that address significant unmet medical needs both in China and globally.

The Company has made significant strides this year in building a portfolio of innovative assets with considerable potential across major global markets.

Our portfolio includes three flagship drug assets that are approaching potential market approval: Cyclosporine Ophthalmic Gel for the treatment of moderate-to-severe dry eye disease ("**DED**"); Atropine Sulfate Eye Drops (NVK002) to control myopia progression in children and adolescents; and Bevacizumab Intravitreal Injection (TAB014) for the treatment of wet age-related macular degeneration ("**wAMD**").

Our pipeline also includes four other promising drug candidates that have achieved significant clinical progress in recent years. These include YUVEZZI™ (formerly known as BRIMOCHOL™ PF) for the treatment of presbyopia; PAN-90806 for the treatment of wAMD and diabetic macular edema ("**DME**"); Melphalan for the treatment of pediatric retinoblastoma; and ZKY001.

Our portfolio also includes commercialized generic products for patients with glaucoma, allergic conjunctivitis and corneal ulcers. Together with our NMPA-approved medical devices, our comprehensive portfolio spans a broad range of major ophthalmic conditions affecting both the front and back of the eye.

Our ambition is to become a leading ophthalmic pharmaceutical company globally, where we see significant opportunities for our products and pipeline. While Greater China remains our primary focus, we are also actively expanding our presence across multiple international markets: the United States, Australia, New Zealand, the Middle East, South Korea, Malaysia, Thailand, Indonesia, Singapore, and Vietnam. Through this growing international footprint, we aim to capture opportunities in key ophthalmic markets while bringing innovative treatment options to more patients worldwide.

HIGHLIGHTS

- **Our flagship products are progressing towards regulatory approval.**

  - Our **Atropine Sulfate Eye Drops (NVK002)** in 0.01% and 0.02% concentrations are under regulatory review for marketing approval. The National Medical Products Administration of China ("**NMPA**") accepted our Abbreviated NDA ("**ANDA**") submission for the 0.01% concentration in January 2025 and our NDA submission for the 0.02% concentration in July 2025. Moreover, the registration applications for both concentrations have been accepted by Australia's Therapeutic Goods Administration ("**TGA**") for regulatory review.

  - The NDA submission for the self-developed Cyclosporine Ophthalmic Gel is currently under regulatory review in China. In addition, the drug's marketing authorization application has been accepted for regulatory review in the Gulf Cooperation Council in May 2026, with Saudi Arabia as the submitting state.

  - The NMPA accepted the NDA for Bevacizumab Intravitreal Injection **(TAB014)** in June 2025. This marks the first NDA filing in China for a bevacizumab-based antibody indicated for the treatment of wAMD.

- **Our presbyopia drug YUVEZZI™ has received regulatory approval in Hainan Boao Super Hospital and Macao.**

  - In June 2026, our innovative presbyopia drug, YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution (2.75%/0.1%), formerly known as BRIMOCHOL™ PF), was approved by the Hainan Provincial Medical Products Administration for use at Boao Super Hospital as a clinically urgent imported drug. We are exploring the marketing-authorization pathway under the policy that enables clinical real-world data generated in the Boao Lecheng Pilot Zone to support registration filings for imported drugs and medical devices.

  - In July 2026, YUVEZZI™ was approved by the Pharmaceutical Administration Bureau of the Government of the Macau Special Administrative Region (ISAF) for the treatment of presbyopia. We are proactively seeking a pathway for YUVEZZI™ under the "Hong Kong-Macau Medicine and Medical Device Connect Program", aiming to facilitate its early commercialization access to the drug for patients across the **Greater Bay Area**.

- **We expanded our strategic global footprint by signing further partnerships and deals.**

  - In January 2026, we expanded our collaboration with AFT Pharmaceuticals Limited for the commercialization of YUVEZZI™ in **Singapore**. We also established a strategic partnership with Senju Pharmaceutical Co., Ltd. for YUVEZZI™ commercialization in **Vietnam**.

- In June 2026, we entered into a distribution and supply agreement with PT Erlangga Edi Laboratories for the commercialization of Cyclosporine Ophthalmic Gel in **Indonesia**.

- In June 2026, we acquired the **global rights** to NVK002 (Atropine Sulfate Eye Drops) from our US partner, reflecting our strong confidence in its long-term value and enabling us to accelerate its global development and commercialization, expand patient access, and further strengthen Zhaoke Ophthalmology's global position in ophthalmology.

- Zhaoke Ophthalmology also entered into two additional Contract Development and Manufacturing Organization ("**CDMO**") partnerships earlier this year.

• **Our financial performance demonstrated our operational resilience.**

- Through disciplined cost management, we have maintained a strong financial position, with RMB715.8 million in cash and cash equivalents and time deposits with original maturity over three months. This provides us with financial flexibility to support the successful launch of our upcoming innovative drugs, while continuing to advance the R&D programs of our broader drug portfolio.

BUSINESS REVIEW

Pipeline Strategy

Zhaoke Ophthalmology has established a portfolio of innovative and generic drugs that address nine major eye diseases across both the front and the back of the eye. These major ophthalmic indications are dry eye disease ("**DED**"), myopia, presbyopia, wet age-related macular degeneration ("**wAMD**"), diabetic macular edema ("**DME**"), glaucoma, corneal epithelial defect ("**CED**"), allergic conjunctivitis and pediatric retinoblastoma ("**RB**", a rare pediatric eye cancer). For some diseases, we have chosen multiple drug candidates, as we believe this is the best way to treat their multiple and complex underlying causes.

Research & Development (R&D)

Research and development underpin all our activities. While we have successfully transformed Zhaoke Ophthalmology into a joint R&D-commercial organization, we remain dedicated to achieving clinical advancements in all our innovative and generic drugs.

Innovative Drugs

Our Company has several strategically important innovative drugs which we expect to move through the pipeline during the next few years.

Cyclosporine Ophthalmic Gel for DED (self-developed)

Overview

Cyclosporine Ophthalmic Gel is an innovative drug developed by Zhaoke Ophthalmology for the treatment of moderate to severe DED.

- Cyclosporine Ophthalmic Gel is a patented hydrogel featuring excellent mucoadhesive properties and prolonged corneal residence time. Adopting nanomicellar formulation technology, Cyclosporine Ophthalmic Gel enhances corneal permeability and improves the bioavailability of cyclosporine. Being preservative-free, it causes minimal ocular irritation and minimal damage to the ocular surface.

- Cyclosporine Ophthalmic Gel is administered once daily at bedtime only, which avoids ocular discomfort and inconvenience caused by daytime dosing. In addition, clinical efficacy can be observed as early as two weeks after treatment initiation. With its two key advantages of once-daily administration and rapid onset of action, Cyclosporine Ophthalmic Gel is expected to improve patient treatment adherence and enhance quality of life.

- In our pivotal Phase III clinical trial ("**COSMO**"), which involved 41 clinical trial centers with a total of 644 patients enrolled, the treatment also showed faster onset of action by demonstrating efficacy as early as two weeks after treatment initiation. By contrast, other Cyclosporine drugs often take more than four weeks to demonstrate clinical benefits.

Updates during and after the Reporting Period

- Our submitted NDA for Cyclosporine Ophthalmic Gel was accepted by the NMPA in May 2025 and is currently under regulatory review in China.

- Cyclosporine Ophthalmic Gel has its Gulf Cooperation Council ("**GCC**") marketing-authorization application under review with Saudi Arabia as the Reference Member State.

- In June 2025, Zhaoke Ophthalmology received FDA clearance of its US Investigational New Drug ("**IND**") application; a Phase III, multicenter, randomized, double-blind, active-controlled clinical study is planned, and Zhaoke Ophthalmology has reached an agreement with the FDA to incorporate data from the completed pivotal Phase III COSMO study and a smaller-scale Phase III clinical trial in China into its US development program. Zhaoke Ophthalmology is in discussions with potential partners to jointly advance the product's development in the United States.

Atropine Sulfate Eye Drops (NVK002) for myopia

Overview

To date, low-concentration atropine has been widely studied and demonstrated to be effective in myopia progression control among children and adolescents. Zhaoke Ophthalmology's Atropine Sulfate Eye Drops are currently positioned as a pioneering, clinically-proven pharmaceutical product for treating the progression of myopia in China.

Zhaoke Ophthalmology has worldwide ownership of all intellectual property, trademarks, regulatory filings, clinical data, manufacturing capabilities, and other related assets associated with NVK002. Nevakar Pharmaceuticals, Inc. ("**Nevakar**"), however, has a perpetual, royalty-free, exclusive license to develop and commercialize NVK002 in the United States.

- Atropine Sulfate Eye Drops (NVK002) adopts a proprietary formulation that effectively resolves the instability of low-concentration atropine. This technology is protected by a portfolio of patents and patent applications worldwide. NVK002 features a pH closer to neutral, making the eye drops more comfortable for children during administration. The eye drops are preservative-free with a 24-month shelf life.

- Zhaoke Ophthalmology has successfully concluded two Phase III clinical trials for Atropine Sulfate Eye Drops in China: a one-year clinical trial ("**Mini-CHAMP**"), and a two-year clinical trial ("**China CHAMP**"). The Mini-CHAMP trial involved 16 centers and 526 patients, and was led by Principal Investigators Professor Qu Xiao Mei, from the Eye and ENT Hospital of Fudan University, and Professor Yang Xiao, from the Zhongshan Ophthalmic Center of Sun Yat-Sen University. The China-CHAMP trial involved 18 centers and 777 patients and was led by Professor Wang Ning Li from Beijing Tongren Hospital as the Principal Investigator.

- Two Phase III trials in China demonstrated statistically significant and clinically meaningful improvements in primary and secondary efficacy endpoints for both 0.01% and 0.02% concentrations versus placebo, with a clear dose-dependent response. The treatment was well tolerated at both concentrations, with a favorable safety and adherence profile.

Updates during and after the Reporting Period

- Following the successful Phase III clinical trials, we submitted an ANDA in January 2025 for the 0.01% concentration and the NDA in July 2025 for the 0.02% concentration. Both applications are currently under the NMPA's regulatory review. Zhaoke Ophthalmology's Atropine Sulfate Eye Drops continues to be well-positioned as potentially one of the top three branded low-concentration atropine product to market.

- Meanwhile, the registration applications for both concentrations of Atropine Sulfate Eye Drops have been accepted for evaluation by Australia's Therapeutic Goods Administration ("**TGA**"), with the 0.01% concentration accepted in January 2026 and the 0.02% concentration in June 2026.

Bevacizumab Intravitreal Injection (TAB014) for wAMD (partnered with BioDlink)

Overview

Our Bevacizumab Intravitreal Injection is the first bevacizumab-based antibody for which a marketing authorization application has been submitted in China for the treatment of wet age-related macular degeneration (wAMD).

- Bevacizumab is a clinically validated, anti-vascular endothelial growth factor (anti-VEGF) drug. Globally, bevacizumab is approved for oncology treatment through intravenous infusion. However, there has been increasing off-label usage of bevacizumab via intravitreal injection for the treatment of wAMD.

- The Phase III clinical trial of Bevacizumab Intravitreal Injection is a randomized, double-blind, and non-inferiority study. The main objective of the study is to evaluate the change from baseline in best-corrected visual acuity (BCVA) at week 52 in a Bevacizumab Intravitreal Injection-treated subject group compared with the Lucentis®-treated subject group.

- The study involves approximately 60 centers and a total of 488 patients and is led by Professor Chen Youxin from Peking Union Medical College Hospital as the Principal Investigator.

Updates during and after the Reporting Period

- Following the successful Phase III clinical trial, a marketing authorization application for Bevacizumab Intravitreal Injection was submitted to the NMPA and was accepted for review in June 2025. This marks the first marketing authorization application for a bevacizumab-based antibody indicated for wAMD in China. The application is currently under the NMPA's regulatory review.

YUVEZZI™ for Presbyopia (formerly known as BRIMOCHOL™ PF) (partnered with Tenpoint)

Overview

YUVEZZI™ is a once-daily, preservative-free pupil-modulating eye drop formulation that can be stored at room temperature, designed to restore near vision lost due to presbyopia.

- YUVEZZI™ is a fixed-dose combination of carbachol, a cholinergic agent, and brimonidine tartrate, an α 2-adrenergic receptor agonist.

- This novel therapy induces pupil constriction, creating a pinhole effect that allows only centrally focused light rays to enter the eye, thereby enhancing image sharpness at near and intermediate distances.

- Zhaoke Ophthalmology's licensing partner for YUVEZZI™ is Tenpoint Therapeutics Ltd. ("**Tenpoint**", formed through the merger of Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc.), a US pharmaceutical company focused on developing innovative ophthalmic therapies.

Updates during and after the Reporting Period

- In January 2026, our partner Tenpoint received regulatory approval from the FDA for the commercialization of YUVEZZI™.

- Following regulatory approval to initiate Phase I and II clinical trials in China, we have completed the Phase II trial.

- In June 2026, we received regulatory approvals from the Hainan Provincial Medical Products Administration for the use of YUVEZZI™ at Boao Super Hospital in Hainan as a clinically urgent imported drug. We are exploring the marketing-authorization pathway under the policy that enables clinical real-world data generated in the Boao Lecheng Pilot Zone to support registration filings for imported drugs and medical devices.

- In July 2026, we also received regulatory approvals from the Pharmaceutical Administration Bureau of the Government of the Macau Special Administrative Region ("**ISAF**") for the treatment of presbyopia. We are proactively seeking a pathway for YUVEZZI™ under the "Hong Kong-Macau Medicine and Medical Device Connect Program", aiming to facilitate its early commercialization access to the drug for patients across the Greater Bay Area.

PAN-90806 (VEGFR2/FGFR inhibitor) for wAMD and DME (partnered with PanOptica)

PAN-90806 is an innovative drug indicated in the treatment of wAMD, as well as DME, the leading cause of blindness in diabetic patients worldwide.

- PAN-90806 ophthalmic solution contains a potent and selective small-molecule inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, IC_{50} = 1.27 nM) as its active ingredient. It also exhibits inhibitory activity against other pro-angiogenic receptor tyrosine kinases (RTKs), including fibroblast growth factor receptors (FGFR1-3), Tie2, and EphB4. PAN-90806 possesses favorable lipophilic and hydrophilic properties. Following topical ocular administration, PAN-90806 is rapidly absorbed through the bulbar and palpebral conjunctiva, diffuses across the sclera, and reaches the suprachoroidal space. Within the suprachoroidal space, it is transported by the choriocapillaris to the choroid and retina, where it inhibits VEGFR2 phosphorylation, thereby suppressing the formation of pathological neovascularization in the posterior segment of the eye.

- If approved as a maintenance therapy, PAN-90806 will bring significant convenience and a less invasive treatment alternative for patients, reducing the frequency of intravitreal injections and other treatment issues associated with mainstream anti-VEGF therapies while at the same time maintaining visual stability.

- PAN-90806 is expected to significantly reduce treatment discontinuation, and therefore slow underlying disease progression through improved patient comfort, acceptance, convenience and compliance.

Updates during and after the Reporting Period

- Following IND approval from the NMPA in November 2025, the Phase Ia trial is currently underway.

ZKY001 (self-developed)

ZKY001 is a seven-amino acid peptide derived from the functional fragment of Thymosin β4 that binds actin, a type of protein that plays a central role in cell structure and movement.

- ZKY001 has broad applications in the healing of corneal wounds and can potentially be used in multiple corneal repair indications.

Melphalan

Melphalan is an alkylating chemotherapy drug that works by damaging the DNA of cancer cells. Melphalan, an alkylating antineoplastic agent, acts on DNA to interfere with DNA replication and cell division and block cancer cell growth and spread. Local administration of melphalan offers potential advantages for retinoblastoma ("**RB**"), a rare paediatric eye tumour.

Updates during and after the Reporting Period

- In July 2025, our proprietary formulation of Melphalan received Orphan Drug Designation ("**ODD**") from the U.S. FDA. We are currently undertaking preparatory work and advancing pre-IND discussions with the FDA.

- Securing ODD delivers significant strategic advantages for Zhaoke Ophthalmology. If Melphalan is successfully developed and receives marketing approval, we will become eligible for seven years of U.S. market exclusivity upon NDA approval. This comprehensive protection encompasses marketing authorization holder ("**MAH**") status, data exclusivity, and crucially, prevents FDA approval of any other melphalan-based product for the RB indication during this period – regardless of formulation innovations.

Innovative Platform – Nanomicelle Hydrogel Technology Platform

We have established a comprehensive research, development and analytical platform covering both nanomicelle formulations and hydrogel formulations, including capabilities for the characterization and analysis of nanomicelle formulations as well as the characterization and evaluation of hydrogel formulations.

Leveraging nanomicelle technology, the platform can significantly enhance the solubility and bioavailability of poorly soluble drug compounds. In addition, gel formulations possess suitable viscosity properties that help prolong the residence time of drugs on the ocular surface, thereby increasing drug exposure and potentially improving therapeutic outcomes. Furthermore, nanomicelle technology and hydrogel formulation technology exhibit synergistic effects. Their combination not only enhances drug delivery efficiency but also improves the storage stability of formulations under room temperature conditions. The Company is currently utilizing this platform to screen potential drug candidates with the aim of identifying compounds whose performance and clinical value can be substantially enhanced through the application of its proprietary platform technologies.

Generic drugs

We have built a balanced development pipeline spanning breakthrough therapies and high-quality generics. As eye disease awareness rises across the world, demand for accessible generics is growing. The depth of our innovative and generic portfolios enables us to deliver comprehensive solutions for ophthalmologists and patients across the region.

Comprehensive Product Portfolio for Glaucoma

Our glaucoma portfolio, which includes various types of medications and the advanced medical device TONO-i, allows us to serve more glaucoma patients across China and empowers physicians to select the most appropriate treatment based on each patient's specific condition.

Glaucoma Eye Drops

All our generic drugs for glaucoma have received NMPA approval for commercialization in China, forming a comprehensive glaucoma product portfolio for the management of intraocular pressure. These generic glaucoma eye drops are:

- **Bimatoprost and Timolol Maleate eye drops (晶贝莹®)** – Approved in February 2023
- **Bimatoprost eye drops (晶贝清®)** – Approved in September 2024
- **Latanoprost eye drops** – Approved in December 2024
- **Latanoprost and Timolol Maleate eye drops** – Approved in March 2025
- **Travoprost eye drops** – Approved in December 2024
- **Travoprost and Timolol Maleate eye drops** – Approved in December 2024

Medical Devices

TONO-i, a device designed to measure intraocular pressure ("**IOP**") – Received an NMPA medical device registration certificate in **August 2025**.

- TONO-i is a portable, contactless tonometer that eliminates the need for anesthesia and reduces the risk of contamination. Its purpose is to improve glaucoma diagnosis and treatment rates in China by enabling ophthalmologists to monitor IOP easily and accurately. This technology also enhances patient compliance with glaucoma treatments by providing instant feedback on their effectiveness.

Other Generic Drugs

- **Epinastine Hydrochloride Eye Drops (利斯敏®)**, a treatment of the symptoms of seasonal allergic conjunctivitis – obtained marketing authorization in **November 2025**. In addition, in **August 2026**, we entered into an Exclusive Distribution and Promotion Agreement with Pharmentum Biopharma covering all sales channels in China (excluding Hong Kong, Macau and Taiwan). The agreement has an initial five-year term and may be automatically extended to ten years, subject to Pharmentum Biopharma meeting the agreed procurement targets and other contractual requirements.

- **Deproteinized Calf Blood Extract Eye Gel (睿保特®)**, a treatment targeting corneal ulcers – The commercialization rights were transferred to Zhaoke Ophthalmology in 2023.

WARNING UNDER RULE 18A.08(3) OF THE LISTING RULES: WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET OUR DRUG CANDIDATES SUCCESSFULLY.

R&D Team

Zhaoke Ophthalmology's R&D capabilities are driven by a diverse and experienced team of ophthalmology specialists with extensive expertise across the global pharmaceutical and biotechnology industries. At the end of the Reporting Period, our R&D team comprised around 70 professionals.

R&D Expenses

For the six months ended June 30, 2026, the Company's R&D expenses were approximately RMB105.8 million, representing a slight decrease of approximately RMB7.3 million from RMB113.1 million for the same period of 2025.

In August 2026, the Phase II clinical trial of YUVEZZI™ was completed. In addition, we initiated the Phase Ia clinical trial for PAN-90806 to evaluate its safety, tolerability and preliminary efficacy.

Our R&D expenses decreased as several key clinical programs progressed toward commercialization and major late-stage clinical trials were completed. While development costs associated with these programs have moderated, we continue to invest in selected pipeline assets and early-stage innovation opportunities to support the Company's long-term growth. We remain committed to a disciplined and market-oriented R&D strategy, focusing on advancing high-potential programs, addressing unmet medical needs and strengthening the long-term value of our product portfolio.

Commercialization

As our flagship innovative drugs advance towards potential regulatory approval, we have continued to strengthen our commercialization capabilities to support their anticipated launches. Zhaoke Ophthalmology has established a comprehensive omni-channel sales and marketing platform encompassing nationwide sales and distribution, extensive hospital coverage and digital channels, providing a strong and scalable foundation for the commercialization of our innovative drug portfolio.

Alongside our innovative pipeline, we have established a broad commercial portfolio in China. We now have eight ophthalmic drugs approved for commercialization in China and two approved medical products, including TONO-i and our heat-compress eye patches, 堡得视®.

We continued to pursue an omni-channel sales and marketing strategy designed to provide broad and effective access to our ophthalmic products across China. Our traditional channels remain an important foundation of this strategy, with our commercialization team continuing to expand our distribution network throughout the Reporting Period.

We have built broad hospital coverage across China, covering top-tier ophthalmic centers and key medical institutions nationwide, including well-recognized eye-care hospitals and leading ophthalmology facilities, such as Beijing Tongren Hospital, the Eye and ENT Hospital of Fudan University, Zhongshan Ophthalmic Center and Aier Eye Hospitals. In parallel, we continued to deepen our relationships with private hospitals, leading ophthalmic institutions and optical centers, further extending the reach of our commercial platform.

Digital engagement is another important pillar of our commercialization strategy, enabling us to connect more effectively with patients, customers and the broader ophthalmology community. Our flagship stores on Tmall (天貓) enhance the accessibility of our products while extending Zhaoke Ophthalmology's brand presence nationwide. Meanwhile, our content-focused WeChat platform, Zhaoke Boshi (兆科博視), has grown into a leading online platform for ophthalmology professionals, with approximately 16,000 followers, representing a significant proportion of ophthalmology professionals in China.

Besides our traditional channels and Digital engagement, we also explore alternative approaches to maximize the value of our products. For our allergic conjunctivitis product, Epinastine Hydrochloride Eye Drops, we entered into a distribution and promotion agreement with Pharmentum Biopharma (Beijing) Co., Ltd. ("**Pharmentum Biopharma**") in August 2026. We maintain an open-minded stance and seek to expand our channels to the fullest extent, so as to drive successful commercialization of our products.

Our commercialization capabilities are entering an important new phase as we prepare to bring our innovative drug portfolio to market. We are strengthening both our traditional and digital channels and leveraging our nationwide sales and marketing infrastructure to support anticipated launches of our flagship drug assets Cyclosporine Ophthalmic Gel, Atropine Sulfate Eye Drops, and Bevacizumab Intravitreal Injection. With an established nationwide commercial platform already in place, we believe we are well positioned to accelerate market access, drive product adoption and maximize the commercial potential of our growing ophthalmic portfolio.

Partnerships and Globalization Efforts

Awareness of ophthalmic diseases continues to grow not only in China but across the world, while access to effective treatments remains limited in many markets. Against this backdrop, Zhaoke Ophthalmology is steadily expanding its international presence, with a focus on bringing our innovative treatments to more patients and capturing opportunities in key ophthalmic markets.

Strategic partnerships remain an important part of our international expansion strategy. In January 2026, we expanded our collaboration with AFT Pharmaceuticals Limited to commercialize YUVEZZI™ in Singapore and agreed a strategic partnership with Senju Pharmaceutical Co., Ltd. for its commercialization in Vietnam. In June 2026, we further strengthened our presence in Southeast Asia through a distribution and supply agreement with PT Erlangga Edi Laboratories for Cyclosporine Ophthalmic Gel in Indonesia.

A significant milestone in our global strategy came in June 2026, when we acquired the global rights to NVK002 (Atropine Sulfate Eye Drops) from our US partner. The acquisition reflects our strong confidence in the product's long-term potential and gives Zhaoke Ophthalmology full control over its development, manufacturing and commercialization worldwide. With these global rights, we are well positioned to accelerate the product's international development, broaden patient access and capture its commercial potential across key global markets.

Alongside the expansion of our international partnerships and product rights, we continued to deliver meaningful regulatory progress overseas during the Reporting Period. In Australia, the registration applications for both concentrations of Atropine Sulfate Eye Drops have been accepted for evaluation by Australia's Therapeutic Goods Administration ("**TGA**"), with the 0.01% concentration accepted in January 2026 and the 0.02% concentration in June 2026. These developments further strengthen the foundation for the international expansion of our innovative ophthalmic portfolio.

Manufacturing

Zhaoke Ophthalmology operates a state-of-the-art manufacturing facility in Nansha, Guangzhou, providing the Company with fully integrated in-house manufacturing capabilities. Equipped with advanced machinery from leading global suppliers, the facility is designed to meet stringent international standards for dosing, filling and packaging, supporting compliance with both China Good Manufacturing Practice ("**GMP**") and PIC/S Good Manufacturing Practice ("**GMP**") requirements.

Our manufacturing capabilities have also been recognized by international pharmaceutical partners, as evidenced by our manufacturing-related collaborations with Somerset Therapeutics LLC and Fareva Group. Zhaoke Ophthalmology also entered into two additional Contract Development and Manufacturing Organization ("**CDMO**") partnerships earlier this year. These CDMO engagements generate profits for the Company, further demonstrating global industry partners' confidence in our manufacturing expertise.

We currently operate four manufacturing lines at our Nansha facility and manufacture in-house all six of our glaucoma eye drops, as well as Epinastine Hydrochloride Eye Drops for the treatment of allergic conjunctivitis. Importantly, both new drugs, Cyclosporine Ophthalmic Gel, our first self-developed innovative drug, and Atropine Sulfate Eye Drops (for which we hold global rights), will also be manufactured at the facility.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) UPDATE

As a responsible corporate citizen, Zhaoke Ophthalmology is committed to fostering a sustainable healthcare sector. We continually assess the environmental and social impact of our operations and implement strategies to strengthen the sustainability of our business.

Our overarching mission, to improve global visual health, drives our dedication to social responsibility. During the Reporting Period, we organized a series of in-person and online health seminars addressing the screening, treatment, and follow-up care of conditions such as glaucoma and corneal diseases, helping to raise awareness and promote early intervention.

We are equally committed to creating a thriving workplace for our employees. Diversity, inclusion, and professional growth remain central to our culture. This year, we launched a new cycle of our highly regarded tiered mentorship program and continued our rotational scheme, offering high-performing talent the opportunity to gain hands-on experience across multiple areas of our business.

Zhaoke Ophthalmology upholds the highest standards of transparency and compliance. As part of this commitment, we publish an annual ESG (Environmental, Social, and Governance) report to share our progress and priorities with stakeholders. In April 2026, we released our sixth ESG report, outlining the strategies and initiatives that guide our socially responsible practices.

FUTURE AND OUTLOOK

We believe 2026 represents an important year for Zhaoke Ophthalmology as our years of investment in innovative drug development begin to translate into regulatory approvals and commercial launches.

We are particularly excited about the progress of our three flagship innovative drug assets: **Cyclosporine Ophthalmic Gel** for moderate-to-severe dry eye disease, **Atropine Sulfate Eye Drops** for myopia progression control in children and adolescents, and **Bevacizumab Intravitreal Injection** for the treatment of wAMD. All three drugs are progressing through the regulatory process in China, and we remain optimistic regarding their regulatory review progress.

These three flagship products address major ophthalmic diseases affecting both the front and back of the eye and have the potential to become important drivers of our future growth.

We have also achieved significant milestones for YUVEZZI™, our innovative treatment for presbyopia. Following the granting of regulatory approvals in June 2026 – for clinically-urgent imported-drug access at Hainan Boao Super Hospital and for marketing authorization in Macao – we are exploring the marketing-authorization pathway under the policy that enables clinical real-world data generated in the Boao Lecheng Pilot Zone to support registration filings for imported drugs and medical devices, and proactively seeking a pathway to market under the "Hong Kong-Macau Medicine and Medical Device Connect Program", with the aim of facilitating early commercialization access to the drug for patients across the Greater Bay Area.

In the remaining months of 2026, preparations for the anticipated launches of our flagship innovative drugs will be among our highest priorities. We will leverage our established nationwide sales and distribution network, digital channels and in-house manufacturing capabilities to ensure commercial readiness upon regulatory approval. In parallel, we will continue to work closely with the relevant regulatory authorities towards the potential approvals of Cyclosporine Ophthalmic Gel, Atropine Sulfate Eye Drops and Bevacizumab Intravitreal Injection, while continuing to explore opportunities for YUVEZZI™ across the Greater Bay Area.

Beyond China, Zhaoke Ophthalmology is also making solid progress in advancing the commercialization of its broader ophthalmic portfolio across international markets. In addition to the continued expansion of YUVEZZI™ across partnered markets, the Company continues to advance the regulatory review of the marketing authorization application for Cyclosporine Ophthalmic Gel in the Gulf Cooperation Council (GCC), while the registration of its generic drug portfolio in Australia are at an advanced stage. For the CDMO business, the marketing authorization application for the Company's first CDMO product is planned to be submitted to the U.S. FDA for regulatory review this year.Subject to relevant marketing authorizations and commercialization progress, the Company expects its overseas business to begin contributing revenue in the second half of 2027.

With our three flagship innovative drugs approaching potential approval, Zhaoke Ophthalmology is entering an important new phase in which our innovative R&D capabilities are increasingly translating into commercial opportunities. Our goal is to have a total of 12 commercialized drugs by the end of 2026. As a result of this, we expect our growing commercial portfolio to support future revenue growth, as we continue to strengthen our commercial foundation.

FINANCIAL REVIEW

Six months ended June 30, 2026 compared to six months ended June 30, 2025

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue	**18,828**	15,803
Cost of sales	**(9,080)**	(7,336)
Gross profit	**9,748**	8,467
Other income	**14,740**	26,268
Other net gain	**21,681**	20,012
R&D expenses	**(105,751)**	(113,050)
General and administrative expenses	**(33,210)**	(30,559)
Selling and distribution expenses	**(24,825)**	(23,421)
Finance costs	**(4,976)**	(4,340)
Loss before taxation	**(122,593)**	(116,623)
Income tax	**–**	–
Loss for the period	**(122,593)**	(116,623)
Other comprehensive income for the period		
Item that may be reclassified subsequently to profit or loss:		
Exchange differences on translation of financial statements of entities with functional currencies other than RMB	**(68,519)**	(78,750)
Total comprehensive income for the period	**(191,112)**	(195,373)
Non-HKFRS Accounting Standards Measures		
Adjusted loss for the period	**(116,105)**	(115,274)

1. Overview

For the six months ended June 30, 2026, we recorded a total loss of approximately RMB122.6 million, as compared with approximately RMB116.6 million for the six months ended June 30, 2025. This was primarily attributable to the lower interest income from bank deposits, reflecting the decline in global interest rates since mid-2025, and higher equity-settled share-based payment expenses recognised under general and administrative expenses. Such share-based payment expenses are non-cash in nature and are recognised over the vesting period based on the relevant vesting conditions.

2. Revenue

Our Group recorded revenue of RMB18.8 million for the six months ended June 30, 2026, as compared with RMB15.8 million for the six months ended June 30, 2025.

Revenue from sale of drugs and products for the six months ended June 30, 2026 amounted to RMB17.6 million, representing a slight increase compared to RMB15.1 million for the same period in 2025.

We also generated revenue of RMB1.0 million from granting the exclusive distribution rights to our worldwide business partners, for the distribution of our innovative drug candidates (30 June 2025: RMB0.7 million). Please find more details in Management Discussion and Analysis under the section "Partnerships and Globalization Efforts". As at June 30, 2026, the aggregated amount of the transaction price allocated to the remaining performance obligations under our Group's existing contracts was around RMB23.4 million. This amount represents revenue expected to be recognized in the future from distribution and supply contracts entered into between the customer and our Group. We will recognize the expected revenue in future throughout the contract period.

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
Revenue from contracts with customers within the scope of HKFRS 15		
Point in time:		
Sale of ophthalmic drugs	**15,369**	11,725
Sale of other drugs	**1,535**	2,622
Sale of ophthalmic products	**725**	757
Over time:		
Income from exclusive distribution rights	**998**	676
Income from CMO services	**201**	23
	18,828	15,803

3. Other Income

Our Group's other income primarily consists of bank interest income and government grants, which represent one-off subsidies we have received from government authorities.

For the six months ended June 30, 2026, our Group's other income decreased to approximately RMB14.7 million, compared to approximately RMB26.3 million for the six months ended June 30, 2025. The decrease was primarily attributable to the reduction in global bank interest rates since mid 2025, which resulted in lower bank interest income for the Reporting Period.

4. Other Net Gain

For the six months ended June 30, 2026, we recorded approximately RMB21.7 million of other net gain, compared to approximately RMB20.0 million of other net gain for the six months ended June 30, 2025. Such net gain primarily consists of net foreign exchange gain incurred during the translation of EUR-denominated, USD-denominated or HKD-denominated assets and liabilities.

5. R&D Expenses

Our Group's R&D expenses primarily consisted of (i) clinical trial professional service fees, including payments to CROs, hospitals and other medical institutions, as well as testing fees incurred for preclinical studies and clinical trials; (ii) depreciation and amortization related to our R&D equipment and facilities; (iii) staff costs, including salaries, bonuses and welfare payments for R&D personnel; (iv) costs of raw materials and consumables used for R&D of our drug candidates; (v) equity-settled share-based payment for R&D personnel; and (vi) utilities.

For the six months ended June 30, 2026, our R&D expenses slightly decreased by approximately RMB7.3 million to approximately RMB105.8 million from approximately RMB113.1 million for the six months ended June 30, 2025. The slight decrease in research and development expenses during the period was mainly due to the differing scale of clinical trial programmes undertaken and completed compared with the corresponding period. As the Group's flagship products advance towards regulatory approval, research and development expenditures were primarily incurred for clinical trial activities, including costs associated with clinical trial centres, as well as the continuation of monitoring, follow-up and testing activities necessary to support the development and regulatory progression of the Group's pipeline products.

The following table sets forth the components of our Group's R&D expenses for the periods indicated:

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Clinical trial professional service fees	**45,305**	46,955
Staff costs	**21,386**	23,638
Depreciation and amortization	**17,327**	17,873
Professional and consultation fee	**9,880**	10,860
Cost of raw materials and consumables used	**3,714**	4,155
Registration and submission fee	**2,539**	530
Testing fee	**143**	3,032
Utilities	**2,206**	1,798
Others	**3,251**	4,209
Total	**105,751**	113,050

6. General and Administrative Expenses

Our general and administrative expenses primarily consist of staff costs, professional service fees for legal, consulting and auditing services, general operating expenses, depreciation in relation to our office equipment and equity-settled share-based payment for those other than R&D personnel and commercialization team.

For the six months ended June 30, 2026, our general and administrative expenses were approximately RMB33.2 million, representing an increase of approximately RMB2.6 million from approximately RMB30.6 million for the six months ended June 30, 2025, which is primarily attributable to the slight increase in employee salaries and benefits, which was mainly related to the increase of equity-settled share-based payment expenses calculated based on vesting condition over periods in the first half of 2026.

7. Selling and Distribution Expenses

Our selling and marketing expenses mainly consist of staff costs for our commercialization team and marketing & conference expenses.

Our selling and distribution expenses slightly increased from RMB23.4 million for the six months ended June 30, 2025 to approximately RMB24.8 million for the six months ended June 30, 2026. Selling and distribution expenses increased slightly during the reporting period, primarily reflecting continued commercial activities to support the growth of the Group's marketed products. The increase was generally in line with revenue growth and was mainly attributable to market development, promotional activities and sales force-related expenses incurred to further enhance product awareness and market penetration.

8. Finance Costs

Our finance costs slightly increased from approximately RMB4.3 million for the six months ended June 30, 2025 to approximately RMB5.0 million for the six months ended June 30, 2026, which was primarily attributable to the adjustment of interest rate applied to bank loans under the cross-border funding arrangement.

9. Loss for the Period

As a result of the above factors, for the six months ended June 30, 2026, we recorded a loss of approximately RMB122.6 million, as compared to a loss of approximately RMB116.6 million for the six months ended June 30, 2025.

10. Non-HKFRS Accounting Standards Measure

To supplement our Group's interim consolidated financial statements, which are presented in accordance with the HKFRS Accounting Standards, we also use adjusted loss for the period as an additional financial measure, which is not required by, or presented in accordance with, the HKFRS Accounting Standards. We believe that this adjusted measure provides useful information to Shareholders and potential investors in understanding and evaluating our Group's interim consolidated results of operations in the same manner as they help our Company's management.

Adjusted loss for the period represents the loss for the period excluding the effect of equity-settled share-based payment expenses. The term adjusted loss for the period is not defined under the HKFRS Accounting Standards. However, we believe that this non-HKFRS Accounting Standards measure is a reflection of our Group's normal operating results by eliminating the potential impact of items that the management does not consider to be indicative of our Group's operating performance. The adjusted loss for the period, as the management of our Group believes, is adopted in the industry where our Group is operating. However, the presentation of the adjusted loss for the period is not intended to be (and should not be) considered in isolation or as a substitute for the financial information prepared and presented in accordance with the HKFRS Accounting Standards. Shareholders and potential investors of our Company should not view the non-HKFRS Accounting Standards measure (i.e. adjusted loss for the period) on a stand-alone basis or as a substitute for results under the HKFRS Accounting Standards, or as being comparable to results reported or forecasted by other companies.

The table below sets forth a reconciliation of the loss for the period to adjusted loss for the period during the periods indicated:

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Loss for the period	**(122,593)**	(116,623)
Add:		
Equity-settled share-based payment expenses	**6,488**	1,349
Adjusted loss for the period	**(116,105)**	(115,274)

Selected Data from Interim Consolidated Statement of Financial Position

	As at June 30, 2026 ***RMB'000*** **(Unaudited)**	As at December 31, 2025 *RMB'000* (Audited)
Total current assets	**1,098,152**	1,373,846
Total non-current assets	**639,861**	561,466
Total assets	**1,738,013**	1,935,312
Total current liabilities	**(321,878)**	(328,407)
Total non-current liabilities	**(27,980)**	(31,018)
Total liabilities	**(349,858)**	(359,425)
Net current assets	**776,274**	1,045,439

11. Liquidity and Source of Funding and Borrowing

Our primary uses of cash are to fund our clinical trials, manufacturing, and the purchase of equipment and raw materials and other expenses. During the Reporting Period, we primarily funded our working capital requirements through net proceeds from the Global Offering. We closely monitor uses of cash and cash balances and strive to maintain a healthy liquidity for our operations.

As at June 30, 2026, the current assets of our Group were approximately RMB1,098.2 million, including cash and cash equivalents of approximately RMB497.6 million, time deposits with original maturity over 3 months of approximately RMB218.2 million, pledged bank deposits of approximately RMB295.6 million and other current assets of approximately RMB86.8 million. As at June 30, 2026, the current liabilities of our Group were approximately RMB321.9 million, including trade and other payables of approximately RMB49.8 million, amounts due to related companies of approximately RMB9.4 million, bank borrowings of approximately RMB248.9 million and other current liabilities of approximately RMB13.8 million.

Amounts due to related companies represent payable for rental, utility paid on behalf and sales incentives and are unsecured, interest-free and repayable with maximum credit terms of 30 days or on demand.

As of June 30, 2026, our Group had secured bank loans of RMB248.9 million which was repayable within one year or on demand.

Our Group adopts conservative treasury policies in cash and financial management. To achieve better risk control and minimize the cost of funds, our Group's treasury is centralized. Cash is generally placed in deposits mostly denominated in USD, HKD and RMB. Our Group's liquidity and financing requirements are reviewed regularly.

12. Pledged Bank Balance

Our pledged bank balance was approximately RMB295.6 million as of June 30, 2026 (as at December 31, 2025: RMB336.4 million), representing bank balances we pledged with banks for banking facilities.

13. Key Financial Ratios

The following table sets forth the components of our key financial ratio for the dates indicated:

	As at June 30, 2026	As at December 31, 2025
Current ratio[(1)]	**3.41**	4.18
Gearing ratio[(2)]	**N/A**[(3)]	N/A[(3)]

Notes:

(1) Current ratio represents current assets divided by current liabilities as of the same date.

(2) Gearing ratio represents interest-bearing borrowings less cash and cash equivalents and time deposits with original maturity over three months, divided by total equity and multiplied by 100% as of the same date.

(3) As of December 31, 2025 and June 30, 2026, we were in a net cash position and thus gearing ratio is not applicable.

14. Contingent Liabilities

As at June 30, 2026, our Group did not have any significant contingent liabilities.

15. Capital Commitment

The capital commitment of our Group as at June 30, 2026 was approximately RMB63.9 million, representing a slight decrease of approximately RMB1.4 million as compared with that of approximately RMB65.3 million as at December 31, 2025, primarily attributable to the progress made in the construction of manufacturing facilities and R&D activities.

16. Employees and Remuneration

As at June 30, 2026, our Group had a total of 285 employees. The following table sets forth the total number of employees by function as of June 30, 2026:

Function	Number of employees	% of the total
Management	3	1.1
R&D	67	23.5
Manufacturing	64	22.4
Quality control	39	13.7
Sales and marketing	70	24.6
Environmental, health and safety	1	0.3
Administrative	41	14.4
Total	285	100.0

The remuneration of the employees of our Group comprises salaries, bonuses, employees provident fund and social security contributions, other welfare payments and equity-settled share-based payment. Our Company's emolument policy is to ensure that the remuneration offered to employees, including executive Directors and senior management, is commensurate with their skills, knowledge, responsibilities and involvement in our Company's affairs. The remuneration packages of our employees are periodically reviewed objectively and determined based on each individual's performance.

The total staff costs incurred by our Group for the six months ended June 30, 2026 was approximately RMB58.6 million, as compared to approximately RMB56.1 million for the six months ended June 30, 2025. The slight increase was primarily attributable to the decrease of approximately RMB2.6 million in employee salaries and benefits in line with the decrease in headcount, which was partially netted off by the increase of equity-settled share-based payment expenses of approximately RMB5.1 million.

17. Foreign Exchange Exposure

During the six months ended June 30, 2026, our Group mainly operated in Chinese Mainland and a majority of its transactions were settled in RMB, the functional currency of our Company's primary subsidiaries. As at June 30, 2026, a significant amount of our Group's cash and cash equivalents was denominated in USD. Except for certain cash and cash equivalents, prepayments on purchases of property, plant and equipment and other payables denominated in foreign currencies, our Group did not have significant foreign currency exposure from its operations as at June 30, 2026. Our Group manages its foreign exchange risk by performing regular reviews of our net foreign exchange exposures and seeks to minimize these exposures whenever possible. We currently do not adopt any long-term contracts, currency borrowings or other means to hedge our foreign currency exposure.

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the six months ended June 30, 2026 – unaudited

		Six months ended June 30,	
		2026	2025
	Notes	***RMB'000***	*RMB'000*
Revenue	3	**18,828**	15,803
Cost of sales		**(9,080)**	(7,336)
Gross profit		**9,748**	8,467
Other income		**14,740**	26,268
Other net gain		**21,681**	20,012
R&D expenses		**(105,751)**	(113,050)
General and administrative expenses		**(33,210)**	(30,559)
Selling and distribution expenses		**(24,825)**	(23,421)
Finance costs	4(a)	**(4,976)**	(4,340)
Loss before taxation	4	**(122,593)**	(116,623)
Income tax	5	**–**	–
Loss for the period		**(122,593)**	(116,623)
Loss per share *(RMB)*	6		
Basic		**(0.22)**	(0.21)
Diluted		**(0.22)**	(0.21)

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended June 30, 2026 – unaudited

		Six months ended June 30,	
		2026	2025
	Notes	***RMB'000***	*RMB'000*
Loss for the period		**(122,593)**	(116,623)
Other comprehensive income for the period			
Item that may be reclassified subsequently to profit or loss:			
Exchange differences on translation of financial statements of entities with functional currencies other than Renminbi ("**RMB**")		**(68,519)**	(78,750)
Total comprehensive income for the period		**(191,112)**	(195,373)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

At June 30, 2026 – unaudited

	Notes	**As at June 30, 2026** ***RMB'000***	As at December 31, 2025 *RMB'000*
Non-current assets			
Property, plant and equipment		**143,230**	158,609
Intangible assets		**476,676**	383,642
Prepayments and deposits	8	**19,955**	19,215
		639,861	561,466
Current assets			
Inventories		**13,687**	14,630
Trade and other receivables	8	**44,734**	56,732
Amounts due from related companies		**28,262**	5,240
Pledged bank balances		**295,641**	336,431
Time deposits with original maturity over three months		**218,211**	1,502
Cash and cash equivalents		**497,617**	959,311
		1,098,152	1,373,846
Current liabilities			
Trade and other payables	9	**49,829**	36,468
Contract liabilities		**2,546**	1,726
Amounts due to related companies		**9,362**	7,259
Bank and other loans		**248,875**	270,371
Lease liabilities		**11,266**	12,583
		321,878	328,407
Net current assets		**776,274**	1,045,439
Total assets less current liabilities		**1,416,135**	1,606,905

	Notes	**As at June 30, 2026** ***RMB'000***	As at December 31, 2025 *RMB'000*
Non-current liabilities			
Lease liabilities		**6,419**	9,404
Contract liabilities		**20,896**	20,905
Long service payment liabilities		**120**	124
Deferred income		**545**	585
		27,980	31,018
Net assets		**1,388,155**	1,575,887
Capital and reserves			
Share capital		**–***	–*
Reserves		**1,388,155**	1,575,887
Total equity		**1,388,155**	1,575,887

* The balance represents amount less than RMB1,000.

NOTES TO THE INTERIM RESULTS ANNOUNCEMENT

(Expressed in Renminbi unless otherwise indicated)

1 BASIS OF PREPARATION

The unaudited consolidated interim financial information set out in this announcement does not constitute the Group's unaudited interim financial report for the six months ended June 30, 2026 but is extracted from that unaudited interim financial report.

The interim financial report has been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, including compliance with Hong Kong Accounting Standard ("**HKAS**") 34, *Interim financial reporting*, issued by the Hong Kong Institute of Certified Public Accountants ("**HKICPA**").

The interim financial report has been prepared in accordance with the same accounting policies adopted in the consolidated financial statements for the financial year ended December 31, 2025, except for the accounting policy changes that are expected to be reflected in the consolidated financial statements for the financial year ending December 31, 2026. Details of any changes in accounting policies are set out in note 2.

The interim financial report is unaudited, but has been reviewed by the Company's Audit Committee.

2 CHANGES IN ACCOUNTING POLICIES

The HKICPA has issued a number of amendments to HKFRS Accounting Standards that are first effective for the current accounting period. Of these, only the amendments to HKFRS 9, *Financial instruments* and HKFRS 7, *Financial instruments: Disclosures – Amendments to the classification and measurement of financial instruments*, are relevant to the Group's financial statements. The impacts of adopting these amendments are discussed below.

Amendments to HKFRS 9, Financial instruments and HKFRS 7, Financial instruments: Disclosures – Amendments to the classification and measurement of financial instruments

The amendments clarify when a financial asset or a financial liability is recognised and derecognised. They also introduce an optional exception that permits an entity to derecognise a financial liability before the settlement date when the financial liability is settled in cash using an electronic payment system, provided that specific criteria are met. None of these developments have had a material effect on how the Group's results and financial position for the current or prior periods have been prepared or presented.

The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

3 REVENUE AND SEGMENT REPORTING

(a) Revenue

The principal activities of the Group are development, manufacturing and marketing of ophthalmic drugs and products.

(i) Disaggregation of revenue

Disaggregation of revenue from contracts with customers by major products or service lines is as follows:

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
Revenue from contracts with customers within the scope of HKFRS 15		
Point in time:		
Sale of ophthalmic drugs	**15,369**	11,725
Sale of other drugs	**1,535**	2,622
Sale of ophthalmic products	**725**	757
Over time:		
Income from exclusive distribution rights	**998**	676
Income from CMO services	**201**	23
	18,828	15,803

The Group's customer base is diversified and no customer (six months ended June 30, 2025: one) with whom transactions have exceeded 10% of the Group's revenue. During the six months ended June 30, 2025, sale of other drugs to this customer amounted to approximately RMB2,622,000, and arose in Chinese Mainland.

(ii) Revenue expected to be recognized in the future arising from contracts with customers in existence at the reporting date

As at June 30, 2026, the aggregated amount of the transaction price allocated to the remaining performance obligations under the Group's existing contracts is RMB23,442,000 (December 31, 2025: RMB22,631,000). This amount represents (i) income from granting of exclusive distribution rights of the Group's products under distribution and supply agreements; and (ii) income from CMO services agreement entered into between the Group and its customers, and will be recognized as income over the remaining contractual period.

(b) Segment reporting

Operating segments are identified on the basis of internal reports that the Group's most senior executive management reviews regularly in allocating resources to segments and in assessing their performances.

The Group's most senior executive management makes resources allocation decisions based on internal management functions and assess the Group's business performance as one integrated business instead of by separate business lines or geographical regions. Accordingly, the Group has only one operating segment and therefore, no segment information is presented.

Geographic information

The following table sets out information about the geographical location of (i) the Group's revenue from external customers and (ii) the Group's property, plant and equipment and intangible assets ("**specified non-current assets**"). The geographical location of customers is based on their operating location. The geographical location of the specified non-current assets is based on the physical location of the asset, in the case of property, plant and equipment, and the location of the operation to which they are allocated, in the case of intangible assets.

	Revenue from external customers		**Specified non-current assets**	
	Six months ended June 30,		**As at June 30,**	As at December 31,
	2026	2025	**2026**	2025
	RMB'000	*RMB'000*	***RMB'000***	*RMB'000*
Hong Kong (place of domicile)	**418**	350	**379,817**	285,755
Chinese Mainland	**17,211**	14,708	**240,089**	256,496
South Korea	**745**	601	**–**	–
Others	**454**	144	**–**	–
	18,828	15,803	**619,906**	542,251

4 LOSS BEFORE TAXATION

Loss before taxation is arrived at after charging/(crediting):

(a) Finance costs

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
Interest on bank and other loans	**4,558**	3,752
Interest on lease liabilities	**418**	588
	4,976	4,340

(b) Other items

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
Amortization of intangible assets	**6,790**	7,063
Depreciation charge		
– owned property, plant and equipment	**15,459**	16,286
– right-of-use assets	**3,973**	4,088
Fair value change of investments recognized in profit or loss		
– realized	**(77)**	(2,352)

5 INCOME TAX

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operated.

The Company is incorporated in the Cayman Islands as an exempted company with limited liability under the Cayman Companies Act.

There is no income tax in the Cayman Islands and accordingly, the operating results reported by the Company, is not subject to any income tax in the Cayman Islands.

No provision for Hong Kong profits tax has been provided for at the rate of 16.5% as the Group's Hong Kong entity sustained a loss for taxation purposes.

No provision for Chinese Mainland corporate income tax has been provided for at a rate of 25% pursuant to the Corporate Income Tax Law of the PRC and the respective regulations, as the Group's PRC entities sustained a loss for taxation purposes.

6 LOSS PER SHARE

(a) Basic loss per share

The calculation of basic loss per share is based on the loss attributable to ordinary equity shareholders of the Company of RMB122,593,000 (six months ended June 30, 2025: RMB116,623,000) and the weighted average of 548,478,914 ordinary shares (six months ended June 30, 2025: 546,139,172 ordinary shares) in issue during the interim period.

(b) Diluted loss per share

Diluted loss per share is the same as basic loss per share for the six months ended June 30, 2026 and 2025, as all of the potential ordinary shares are anti-dilutive.

7 DIVIDENDS

No dividends have been paid or declared by the Company during the six months ended June 30, 2026 and 2025.

8 TRADE AND OTHER RECEIVABLES

As of the end of the reporting period, the ageing analysis of trade debtors, based on the invoice date and net of loss allowance, is as follows:

	As at June 30, 2026	As at December 31, 2025
	RMB'000	*RMB'000*
Within 1 month	**1,648**	10,894
1 to 2 months	**2,318**	1,562
2 to 3 months	**567**	796
Over 3 months but within 6 months	**698**	807
Over 6 months	**405**	40
Trade receivables, net of loss allowance	**5,636**	14,099
Value-added tax recoverable	**6,215**	8,109
Prepayments to suppliers	**46,337**	36,411
Other receivables	**6,501**	17,328
	59,053	61,848
	64,689	75,947
Represented by:		
Non-current portion	**19,955**	19,215
Current portion	**44,734**	56,732
	64,689	75,947

Trade receivables are due within 30–90 days from the date of billing.

Apart from the non-current portion disclosed above, all of the other trade and other receivables are expected to be recovered or recognized as expenses within one year.

9 TRADE AND OTHER PAYABLES

As of the end of the reporting period, the ageing analysis of trade creditors, based on the invoice date, is as follows:

	As at June 30, 2026	As at December 31, 2025
	RMB'000	*RMB'000*
Within 1 month	**41**	25
1 to 3 months	**18**	1
Over 3 months but within 6 months	**39**	–
Over 6 months	**135**	294
Trade payables	**233**	320
Payables for purchase of property, plant and equipment	**2,355**	3,468
Payroll payables	**9,970**	12,231
Accrued costs for R&D expenses	**28,376**	11,910
Payables for purchase of materials	**1,320**	1,605
Accrued office expenses and others	**3,630**	6,189
Other taxes payables	**3,945**	745
	49,596	36,148
Trade and other payables	**49,829**	36,468

All of the trade and other payables are expected to be settled within one year or are repayable on demand.

OTHER INFORMATION

EVENTS AFTER THE REPORTING PERIOD

There was no other significant event affecting our Group which occurred after the end of the Reporting Period up to the date of this announcement.

INTERIM DIVIDEND

The Board does not recommend the distribution of an interim dividend for the six months ended June 30, 2026.

COMPLIANCE WITH THE CG CODE

Pursuant to code provision C.2.1 of Part 2 of the CG Code, the roles of chairman and chief executive should be separate and not be performed by the same individual. Dr. Li Xiaoyi currently serves as both the Chairman and the CEO. Dr. Li Xiaoyi has been operating and managing our Group since its establishment. Our Board believes that vesting the roles of both CEO and Chairman in the same person has the benefit of ensuring consistent leadership and efficient discharge of executive functions within our Group. We consider that the balance of power and authority of the present arrangement will not be impaired as the Board comprises six other experienced and high-caliber individuals who would be able to offer advice from various perspectives. In addition, for major decisions of our Group, our Board will consult with appropriate Board committees and senior management.

Therefore, our Directors consider that the present arrangement is beneficial to and in the interest of our Company and our Shareholders as a whole and the deviation from Code provision C.2.1 of Part 2 of the CG Code is appropriate in such circumstance. The Board will continue to review the effectiveness of the corporate governance structure of our Group in order to assess whether the separation of the roles of Chairman and CEO is necessary.

In response to the amendments to the CG Code effective July 1, 2025, the Board has approved changes to the terms of reference for the nomination committee. Additionally, Mr. Wong Hin Wing, Prof. Lo Yuk Lam, and Ms. Leelalertsuphakun Wanee have been appointed as members of the nomination committee. For details, see announcements of the Company dated June 30, 2025 and July 2, 2025.

Our Company is committed to maintaining a high standard of corporate governance (which is of critical importance to our development) to protect the interest of the Shareholders. Save as disclosed above, our Directors consider that we have complied with all applicable code provisions of the CG Code as set out in Appendix C1 to the Listing Rules during the Reporting Period and up to the date of this announcement.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS

We have adopted the Model Code set out in Appendix C3 to the Listing Rules as its securities code to regulate the dealing by the Directors in securities of our Company.

Having made specific enquiry of all Directors, all of them have confirmed that they have complied with the Model Code during the Reporting Period and up to the date of this announcement. No incident of non-compliance with the Model Code by the employees who are likely to be in possession of inside information of our Company was noted by us.

USE OF PROCEEDS FROM THE GLOBAL OFFERING

Our Company's Shares were listed on the Stock Exchange on April 29, 2021 with a total of 123,567,500 offer Shares issued. The net proceeds from the Global Offering amounted to approximately HK$1,932.3 million, after deducting the underwriting fees, commissions and related Listing expenses. As of June 30, 2026, such net proceeds were utilized as follows:

Use of proceeds from Listing	Amount of net proceeds for planned applications *HK$ million*	Percentage of total net proceeds *%*	Utilized net proceeds as of December 31, 2025 *HK$ million*	Utilized net proceeds from January 1, 2026 to June 30, 2026 *HK$ million*	Unutilized net proceeds as of June 30, 2026 *HK$ million*	Expected time frame for unutilized amount
For the clinical development and commercialization of our two Core Products	618.34	32.00%	364.59	30.64	223.11	
1. Allocated to CsA Ophthalmic Gel	438.64	22.70%	273.55	30.32	134.77	By the end of 2026
2. Allocated to ZKY001	179.70	9.30%	91.04	0.32	88.34	By the end of 2026
The continuing R&D activities as well as commercialization of the other drug candidates in our pipeline	888.86	46.00%	742.24	57.46	89.16	
1. The continuing R&D activities of other key drug candidates	579.69	30.00%	463.58	41.53	74.58	By the end of 2026
2. The continuing R&D activities of other innovative and generic drug candidates	57.97	3.00%	57.97	–	–	–
3. The milestone payments of our other in-licensed drug candidate	96.62	5.00%	96.62	–	–	–
4. The further expansion of our sales and marketing team in anticipation of new product launches in the coming year	154.58	8.00%	124.07	15.93	14.58	By the end of 2026
Carrying out the production line expansion of our advanced Nansha manufacturing facility in anticipation of our product launches in the coming years	135.27	7.00%	135.27	–	–	–
Our business development activities and the expansion of drug pipelines	96.62	5.00%	96.62	–	–	–
Working capital and other general corporate purposes	193.23	10.00%	193.23	–	–	–
	1,932.32	100.00%	1,531.95	88.10	312.27	

As at June 30, 2026, all the unused net proceeds are held by our Company in short-term deposits with licensed banks or authorized financial institutions in Hong Kong and the PRC.

The expected timeline for utilizing the net proceeds from the Global Offering is based on the best estimation of future market conditions made by our Company and is subject to changes in accordance with our actual business operation. Going forward, the net proceeds will be applied in the manner as set out in "Future Plans and Use of Proceeds" of the Prospectus. As of the date of this announcement, there is no change in the intended use of net proceeds as previously disclosed in the Prospectus.

PURCHASE, SALE OR REDEMPTION OF OUR COMPANY'S LISTED SECURITIES

During the Reporting Period, the Company repurchased 1,653,000 ordinary shares on the Stock Exchange at an aggregate consideration of HK$4.4 million (including expenses). As at June 30, 2026, such repurchased shares had not yet been cancelled and were therefore included in other reserve as at June 30, 2026. The shares were repurchased for cancellation and were not held as treasury shares.

The details of the shares repurchased are as follows:

Month of repurchase	No. of ordinary shares repurchased	Price per share		Aggregate purchase price (including expenses)
		Highest	Lowest	
		HK$	*HK$*	*HK$'000*
June 2026	1,653,000	2.832	2.4806	4,403

Save as disclosed above, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities and/or sold any treasury shares during the Reporting Period.

MATERIAL LITIGATION

We were not involved in any material litigation or arbitration during the six months ended June 30, 2026. Our Directors are also not aware of any material litigation or claims that were pending or threatened against our Group during the six months ended June 30, 2026.

REVIEW OF INTERIM RESULTS BY AUDIT COMMITTEE

The Audit Committee comprises one non-executive Director, namely, Ms. Tiantian Zhang, and two independent non-executive Directors, namely, Mr. Wong Hin Wing and Mr. Liew Fui Kiang. The chairman of the Audit Committee is Mr. Wong Hin Wing.

The Audit Committee has reviewed the accounting principles and practices adopted by our Group and discussed auditing, internal control and financial reporting matters, including the review of our Group's unaudited interim financial report for the six months ended June 30, 2026.

The Audit Committee reviews and assesses the effectiveness of our Company's risk management and internal control systems which cover all material financial, operational and compliance controls. The Audit Committee also reviews regularly the corporate governance structure and practices within our Company and monitors compliance fulfillment on an ongoing basis.

PUBLICATION OF THE 2026 CONSOLIDATED INTERIM RESULTS AND INTERIM REPORT

This announcement is published on the website of the Stock Exchange (www.hkexnews.hk) and our website (zkoph.com). The interim report of our Company for the six months ended June 30, 2026 containing all the information in accordance with the requirements under the Listing Rules, will be despatched to the Shareholders (if so requested by Shareholders) and published on the respective websites of the Stock Exchange and our Company in due course.

APPRECIATION

We wish to express our sincere gratitude to our Shareholders and business partners for their continued support, and to our employees for their dedication and hard work.

DEFINITIONS

"ANDA"	abbreviated new drug application, an application for a generic drug to an approved drug in China
"Audit Committee"	the audit committee of the Board
"Board" or "Board of Directors"	the board of directors of our Company
"CDE"	the Center for Drug Evaluation of NMPA (國家藥品監督管理局藥品審評中心), a division of the NMPA mainly responsible for review and approval of IND and NDA
"CED"	corneal epithelial defect
"CEO"	the chief executive officer of our Company
"CG Code"	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules

"Chairman"	chairman of the Board
"China" or "the PRC"	the People's Republic of China excluding, for the purpose of this interim results announcement, Hong Kong, Macau Special Administrative Region and Taiwan
"CMO services"	Contract Manufacturing Organization Services
"Company", "our Company", "we" or "Zhaoke Ophthalmology"	Zhaoke Ophthalmology Limited
"conjunctivitis"	a disease characterized by the inflammation of the conjunctiva
"connected person(s)"	has the meaning ascribed thereto under the Listing Rules
"connected transaction(s)"	has the meaning ascribed thereto under the Listing Rules
"Controlling Shareholder(s)"	has the meaning ascribed thereto under the Listing Rules
"Core Product(s)"	has the meaning ascribed to it in Chapter 18A of the Listing Rules; for the purpose of this interim results announcement, our Core Products refer to CsA ophthalmic gel and ZKY001
"corneal ulcers"	open sores or wounds that form on the cornea
"CRO"	contract research organization, a company that provides support to pharmaceutical companies by providing a range of professional research services on a contract basis
"CsA"	a selective immuno-suppressant that inhibits calcineurin, an activator of T cells
"CSO"	the chief science officer of our Company
"DED"	dry eye disease, a common condition that occurs when tears are unable to provide adequate lubrication for eyes
"Director(s)"	the director(s) of our Company, including all executive directors, non-executive directors and independent non-executive directors
"DME"	diabetic macular edema, a complication of diabetes that causes damage to the macula

"EU"	the European Union
"EUR"	European Dollar, the lawful currency of the European Union
"Executive Committee"	the executive committee of the Board
"FAREVA Group"	Fareva Group, is a France-based, privately held pharmaceutical company with diversified operations across pharmaceuticals, cosmetics, household care, and specialty chemicals, supported by over 30 years of expertise and advanced facilities
"FDA"	the United States Food and Drug Administration
"GCC"	Gulf Cooperation Council, a regional alliance of six Arab monarchies in the Persian Gulf
"glaucoma"	a group of eye diseases that are usually characterized by progressive structural and functional changes of the optic nerve
"Global Offering"	the offer for subscription of the shares as described in the Prospectus
"GMP"	good manufacturing practice
"Greater China"	the PRC, Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
"Group", "our Group", "we" or "us"	our Company and its subsidiaries
"HKFRS"	Hong Kong Financial Reporting Standards
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Hong Kong dollars" or "HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"IND"	investigational new drug, the application for which is the first step in the drug review process by regulatory authorities to decide whether to permit clinical trials. Also known as clinical trial application, or CTA, in China

"Lee's Pharm"	Lee's Pharmaceutical Holdings Limited (李氏大藥廠控股有限公司), an exempted company incorporated in the Cayman Islands with limited liability whose shares are listed on the Main Board of the Stock Exchange (stock code: 950)
"Lee's Pharm International"	Lee's Pharmaceutical International Limited, a limited liability company incorporated in the British Virgin Islands on August 1, 2001 and a subsidiary of Lee's Pharm
"Listing" or "IPO"	the listing of our Shares on the Main Board of the Stock Exchange
"Listing Date"	April 29, 2021, being the date on which dealings in our Shares first commence on the Main Board of the Stock Exchange
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
"MAH"	Marketing Authorization Holder, an authorization acquired by the holder upon receipt of the drug registration certificate granted by the NMPA, which allows the holder to partner with contract manufacturing organizations to manufacture the drug concerned
"Main Board"	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with GEM of the Stock Exchange
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules
"NDA"	new drug application, an application through which the drug sponsor formally proposes that the relevant regulatory authority approve a new drug for sales and marketing
"NK"	neurotrophic keratitis, a rare degenerative corneal disease
"NMPA"	National Medical Products Administration, the institution that performs the functions of China Food and Drug Administration instead according to the Institutional Reform Plan of the State Council of the PRC
"ODD"	Orphan Drug Designation

"Post-IPO Share Option Scheme"	the post-IPO share option scheme adopted by our Company on April 1, 2021, effective from the Listing Date, as amended from time to time, the principal terms of which are set out in "Appendix IV – Statutory and General Information – D. Share Option Schemes – 2. Post-IPO Share Option Scheme" in the Prospectus
"Pre-IPO Share Option Scheme"	the pre-IPO share option scheme adopted by our Company on November 17, 2020, the principal terms of which are set out in "Appendix IV – Statutory and General Information – D. Share Option Schemes – 1. Pre-IPO Share Option Scheme" in the Prospectus
"Prospectus"	the prospectus issued by our Company dated April 16, 2021
"pterygium"	a growth in the cornea or the conjunctiva
"R&D"	research and development
"RB"	pediatric retinoblastoma
"Reporting Period"	the six months ended June 30, 2026
"RMB"	Renminbi
"SFO"	Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
"Share(s)"	ordinary shares in the share capital of our Company of US$0.00000025 each
"Shareholder(s)"	holder(s) of Shares
"Somerset Therapeutics"	Somerset Therapeutics LLC, a leading American ophthalmic pharmaceutical privately held company, focuses on manufacturing and supplying generic medicines in the US market
"South Korea"	the Republic of Korea, its territories, its possessions and all areas subject to its jurisdiction
"Stock Exchange"	The Stock Exchange of Hong Kong Limited, a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited

"Tenpoint"	Tenpoint Therapeutics Limited, a global clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye, is one of our business partners
"TPRK"	transepithelial photorefractive keratectomy, a surgical treatment for myopia
"United States" or "U.S."	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
"U.S. dollars" or "US$"	United States dollars, the lawful currency of the U.S.
"VEGF"	vascular endothelial growth factor, a signal protein produced by cells that stimulates the formation of blood vessels
"wAMD"	wet age-related macular degeneration

By order of the Board
Zhaoke Ophthalmology Limited
Dr. Li Xiaoyi
Chairman and executive Director

Hong Kong, August 28, 2026

As at the date of this announcement, the Board comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as executive Directors, Ms. Leelalertsuphakun Wanee and Ms. Tiantian Zhang as non-executive Directors, and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.